Recurrent Ovarian High Grade Serous Adenocarcinoma

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Recurrent Ovarian High Grade Serous Adenocarcinoma trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

RecruitingPhase 1

NCT05950464

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo…

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer tha…

United States65 participantsStarted 2023-12-18

Treatment: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure

RecruitingPhase 1

NCT04633239

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that r…

United States42 participantsStarted 2021-07-02

Treatment: Abemaciclib, Biopsy Procedure

RecruitingPhase 1

NCT05039801

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to…

United States54 participantsStarted 2021-09-09

Treatment: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274

RecruitingPhase 1/2

NCT05920798

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalpha…

United States40 participantsStarted 2023-09-28

Treatment: Biopsy, Biospecimen Collection

All recent trials (30 shown)

Active — Not RecruitingPhase 2/3

NCT02839707

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O…

This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovari…

United States444 participantsStarted 2017-06-23

Treatment: Atezolizumab, Bevacizumab

Active — Not RecruitingPhase 1/2

NCT01116648

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recu…

This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well they work compared t…

United States155 participantsStarted 2010-04-14

Treatment: Biopsy Procedure, Biospecimen Collection

Recurrent Ovarian High Grade Serous Adenocarcinoma

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo…

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

All recent trials (30 shown)

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O…

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recu…

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo…

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

All recent trials (30 shown)

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent O…

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recu…

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansi…

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovaria…

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Prim…

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and…

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube…

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

A Study to Investigate LYL797 in Adults With Solid Tumors

A Biomarker Screening Protocol for Participants With Solid Tumors

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab…

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary P…

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colo…

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Ce…

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi